首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1370922

肾癌药物市场-2018-2028年全球产业规模、份额、趋势、机会与预测，依治疗类别、药理学类别（血管新生抑制剂、单株抗体、mTOR抑制剂）、地区、竞争细分

Kidney Cancer Drugs Market-Global Industry Size, Share, Trends, Opportunity, & Forecast, 2018-2028 Segmented By Therapeutic Class, Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors), Region, Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2022年全球肾癌药物市场估值达62.8亿美元，预计在预测期内将出现大幅增长，预计复合年增长率（CAGR）为6.50%，预计到2022年将达到91.8亿美元2028. 肾癌，医学上称为肾细胞癌(RCC)，是一种起源于肾臟的复杂疾病，肾臟是负责过滤血液中废物和多余液体以产生尿液的重要器官。肾癌的治疗是一项具有挑战性的任务，需要有效的策略。随着医学研究的进步和药物创新的加速，肾癌药物市场的成长和演变受到几个关键驱动因素的推动。

主要市场驱动因素：

1.研究和开发的进步：製药公司、学术机构和研究组织正在投入大量资源，以深入了解肾癌的基础生物学。这项投资确定了导致肾癌发生和进展的关键分子途径、基因突变和生物标记。这些进步为标靶治疗的发展奠定了基础，标靶治疗的重点是抑制与癌症生长有关的特定分子或途径。例子包括酪胺酸激酶抑制剂 (TKI) 和 mTOR 抑制剂，它们透过提供更有效和毒性更低的疗法而改变了肾癌的治疗。

市场概况
预测期	2024-2028
2022 年市场规模	62.8亿美元
2028 年市场规模	91.8亿美元
2023-2028 年复合年增长率	6.50%
成长最快的细分市场	标靶治疗
最大的市场	北美洲

2.免疫疗法革命：免疫疗法的出现为包括肾臟癌在内的多种癌症的治疗带来了革命。免疫检查点抑制剂，例如PD-1和PD-L1抑制剂，透过利用人体的免疫系统来识别和攻击癌细胞，显示出了显着的功效。这些疗法不仅延长了生存率，也为创新的联合疗法铺平了道路。研究人员正在积极探索如何将标靶疗法与免疫疗法协同发挥作用，以实现更强劲的反应。免疫疗法的出现开创了癌症治疗的新时代。
3.不断涌现的临床试验创新：临床试验是评估肾癌新药安全性和有效性的基础。创新的试验设计，结合生物标记驱动的终点和适应性试验设计，正在推动药物开发向前发展。生物标记驱动的试验能够选择最有可能对特定治疗产生反应的患者，而适应性试验设计允许根据累积的资料进行即时修改，从而提高试验效率和决策。

主要市场挑战：

1.抗药性和治疗异质性：儘管标靶治疗和免疫疗法取得了进展，但对这些治疗的抗药性的发展仍然是肾癌的重大挑战。肿瘤会随着时间的推移而适应，使曾经有效的疗法变得无效。这突显出需要持续研究以了解抗药性机制并制定克服抗药性的策略。此外，肾癌不是一种同质性疾病，不同的亚型和基因变异导致治疗反应的改变。开发对不同患者群体有效的疗法是一项复杂的工作。
2.缺乏预测性生物标记：缺乏可靠的预测性生物标记阻碍了有效肾癌药物的开发。能够准确识别可能对特定治疗产生反应的患者的生物标记对于个人化医疗方法至关重要。目前，没有任何一种生物标记能够对所有患者和治疗方式表现出一致的预测价值。缺乏可靠的生物标记使得医疗保健专业人员很难做出明智的治疗决策。
3.免疫相关不良事件 (irAE)：免疫疗法虽然在癌症治疗中具有变革性，但由于会激活免疫系统，因此可能导致免疫相关不良事件 (irAE)。这些事件可能会影响多个器官，因此需要仔细管理以平衡免疫活化与潜在危害。 irAE 的发生和严重程度会影响患者的依从性、生活品质和整体治疗成功。

主要市场趋势：

1.个人化医疗革命：个人化医疗的出现为改善肾癌治疗的患者预后提供了广阔的前景。精准肿瘤学根据个别基因图谱和生物标记表达客製化干预措施，摆脱一刀切的方法。基因组学和分子诊断的进步使肿瘤学家能够识别导致患者肾癌的特定基因突变或变化。这些资讯可以指导标靶治疗的处方，提高成功的可能性，提高药物疗效并最大限度地减少不良反应。
2.联合疗法：同时或相继合併多种治疗正成为增强肾癌治疗效果和克服抗药性的强大策略。透过将标靶疗法与免疫疗法或其他治疗方式相结合而实现的协同作用提供了攻击癌细胞的多方面方法。对能够最大限度提高治疗效果的新型组合的探索正在推动对肾癌药物的需求。实现更好的反应和延长疾病控制的潜力正在激发合作努力，以确定不同治疗方法之间的最佳协同作用。

细分洞见：

治疗类别洞察： 2022年，免疫治疗领域主导肾癌药物市场，占最大份额。人们对创新免疫疗法和免疫肿瘤药物的日益青睐正在推动标靶疗法的使用，特别是在特定患者亚群中或作为后期治疗，这增加了需求。

区域见解：北美已成为全球肾癌药物市场的领导者。这可以归因于广泛的医疗支出和有利的治疗报销规定。此外，人口中吸烟、高血压和糖尿病的高盛行率，以及主要製药商的存在，使得亚太地区在预测期内肾癌药物市场将经历最高的成长。

The Global Kidney Cancer Drugs Market achieved a valuation of USD 6.28 Billion in 2022, and it is expected to experience substantial growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.50% and is expected to reach USD 9.18 Billion by 2028. Kidney cancer, medically known as renal cell carcinoma (RCC), is a complex disease originating in the kidneys, vital organs responsible for filtering waste and excess fluids from the blood to produce urine. The treatment of kidney cancer is a challenging task, demanding effective strategies. The growth and evolution of the kidney cancer drugs market are being propelled by several key drivers as medical research advances and pharmaceutical innovation accelerates.

Key Market Drivers:

1. Advancements in Research and Development: Significant resources are being invested by pharmaceutical companies, academic institutions, and research organizations to gain a deep understanding of the underlying biology of kidney cancer. This investment has led to the identification of crucial molecular pathways, genetic mutations, and biomarkers responsible for driving the development and progression of kidney cancer. These advancements have laid the foundation for the development of targeted therapies, which focus on inhibiting specific molecules or pathways involved in cancer growth. Examples include tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, which have transformed kidney cancer treatment by providing more effective and less toxic therapies.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 6.28 Billion
Market Size 2028	USD 9.18 Billion
CAGR 2023-2028	6.50%
Fastest Growing Segment	Targeted Therpay
Largest Market	North America

2. Immunotherapy Revolution: The advent of immunotherapies has brought about a revolution in the treatment of various cancers, including kidney cancer. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable efficacy by harnessing the body's immune system to recognize and attack cancer cells. These therapies have not only extended survival rates but have also paved the way for innovative combination therapies. Researchers are actively exploring how to synergize targeted therapies with immunotherapies to achieve even more robust responses. The emergence of immunotherapies has ushered in a new era of cancer treatment.

3. Rising Clinical Trial Innovation: Clinical trials are fundamental in evaluating the safety and efficacy of new kidney cancer drugs. Innovative trial designs, incorporating biomarker-driven endpoints and adaptive trial designs, are propelling drug development forward. Biomarker-driven trials enable the selection of patients most likely to respond to a particular therapy, while adaptive trial designs allow real-time modifications based on accumulating data, enhancing trial efficiency and decision-making.

Key Market Challenges:

1. Resistance and Treatment Heterogeneity: Despite the progress made in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Tumors can adapt over time, rendering once-effective therapies ineffective. This highlights the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Moreover, kidney cancer is not a homogeneous disease, with different subtypes and genetic variations contributing to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor.

2. Lack of Predictive Biomarkers: The absence of reliable predictive biomarkers hinders the development of effective kidney cancer drugs. Biomarkers that can accurately identify patients likely to respond to a particular treatment are essential for personalized medicine approaches. Currently, no single biomarker has demonstrated consistent predictive value across all patients and treatment modalities. The lack of reliable biomarkers makes it challenging for healthcare professionals to make informed treatment decisions.

3. Immune-Related Adverse Events (irAEs): Immunotherapies, while transformative in cancer treatment, can lead to immune-related adverse events (irAEs) as they activate the immune system. These events can affect various organs, necessitating careful management to balance immune activation against potential harm. The occurrence and severity of irAEs can impact patient compliance, quality of life, and overall treatment success.

Key Market Trends:

1. Personalized Medicine Revolution: The advent of personalized medicine is offering promising prospects for improved patient outcomes in kidney cancer treatment. Precision oncology tailors interventions based on individual genetic profiles and biomarker expression, moving away from a one-size-fits-all approach. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. This information guides the prescription of targeted therapies with a higher likelihood of success, enhancing drug efficacy and minimizing adverse effects.

2. Combination Therapies: Combining multiple treatments simultaneously or sequentially is emerging as a powerful strategy to enhance treatment efficacy and overcome resistance in kidney cancer. The synergy achieved by combining targeted therapies with immunotherapies or other treatment modalities offers a multifaceted approach to attacking cancer cells. The exploration of novel combinations that maximize treatment outcomes is driving the demand for kidney cancer drugs. The potential to achieve better responses and prolonged disease control is spurring collaborative efforts to identify the optimal synergy between different therapeutic approaches.

Segmental Insights:

Therapeutic Class Insights: In 2022, the immunotherapy segment dominated the Kidney Cancer Drugs Market, holding the largest share. The increasing preference for innovative immunotherapies and immune-oncologic drugs is driving the use of targeted therapies, particularly in specific patient subpopulations or as later lines of treatment, which is boosting demand.

Regional Insights: North America has established itself as the leader in the Global Kidney Cancer Drugs Market. This can be attributed to widespread healthcare spending and favorable reimbursement regulations for therapy. Furthermore, the high prevalence of smoking, hypertension, and diabetes among its population, along with the presence of major pharmaceutical manufacturers, positions Asia-Pacific to experience the highest growth in the kidney cancer drugs market during the forecast period.

Key Market Players

Novartis AG
Pfizer Inc.
Bayer AG
Genentech Inc.
Bristol-Myers Squibb
Eisai Co., Ltd.
Exelixis Inc
Prometheus Laboratories Inc
Glaxosmithkline PLC.
F. Hoffmann-LA Roche AG

Report Scope:

In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Kidney Cancer Drugs Market, By Therapeutic Class:

Targeted Therapy
Immunotherapy
Chemotherapy

Kidney Cancer Drugs Market, By Pharmacologic Class:

Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
Cytokine Immunotherapy (IL-2)

Global Kidney Cancer Drugs Market, By Region:

North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.

Available Customizations:

Global Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Kidney Cancer Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
- 5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
- 5.2.3. By Company (2022)
- 5.2.4. By Region
5.3. Market Map

6. North America Kidney Cancer Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Therapeutic Class
- 6.2.2. By Pharmacologic Class
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Kidney Cancer Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Therapeutic Class
    - 6.3.1.2.2. By Pharmacologic Class
- 6.3.2. Mexico Kidney Cancer Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Therapeutic Class
    - 6.3.2.2.2. By Pharmacologic Class
- 6.3.3. Canada Kidney Cancer Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Therapeutic Class
    - 6.3.3.2.2. By Pharmacologic Class

7. Europe Kidney Cancer Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value & Volume
7.2. Market Share & Forecast
- 7.2.1. By Therapeutic Class
- 7.2.2. By Pharmacologic Class
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Kidney Cancer Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Therapeutic Class
    - 7.3.1.2.2. By Pharmacologic Class
- 7.3.2. Germany Kidney Cancer Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Therapeutic Class
    - 7.3.2.2.2. By Pharmacologic Class
- 7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Therapeutic Class
    - 7.3.3.2.2. By Pharmacologic Class
- 7.3.4. Italy Kidney Cancer Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Therapeutic Class
    - 7.3.4.2.2. By Pharmacologic Class
- 7.3.5. Spain Kidney Cancer Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Therapeutic Class
    - 7.3.5.2.2. By Pharmacologic Class

8. Asia-Pacific Kidney Cancer Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value & Volume
8.2. Market Share & Forecast
- 8.2.1. By Therapeutic Class
- 8.2.2. By Pharmacologic Class
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Kidney Cancer Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Therapeutic Class
    - 8.3.1.2.2. By Pharmacologic Class
- 8.3.2. India Kidney Cancer Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Therapeutic Class
    - 8.3.2.2.2. By Pharmacologic Class
- 8.3.3. South Korea Kidney Cancer Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapeutic Class
    - 8.3.3.2.2. By Pharmacologic Class
- 8.3.4. Japan Kidney Cancer Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapeutic Class
    - 8.3.4.2.2. By Pharmacologic Class
- 8.3.5. Australia Kidney Cancer Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapeutic Class
    - 8.3.5.2.2. By Pharmacologic Class

9. South America Kidney Cancer Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Therapeutic Class
- 9.2.2. By Pharmacologic Class
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Kidney Cancer Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Therapeutic Class
    - 9.3.1.2.2. By Pharmacologic Class
- 9.3.2. Argentina Kidney Cancer Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Therapeutic Class
    - 9.3.2.2.2. By Pharmacologic Class
- 9.3.3. Colombia Kidney Cancer Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Therapeutic Class
    - 9.3.3.2.2. By Pharmacologic Class

10. Middle East and Africa Kidney Cancer Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Therapeutic Class
- 10.2.2. By Pharmacologic Class
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Kidney Cancer Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Therapeutic Class
    - 10.3.1.2.2. By Pharmacologic Class
- 10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Therapeutic Class
    - 10.3.2.2.2. By Pharmacologic Class
- 10.3.3. UAE Kidney Cancer Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Therapeutic Class
    - 10.3.3.2.2. By Pharmacologic Class

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
- 15.6.1. Novartis AG
- 15.6.2. Pfizer Inc.
- 15.6.3. Bayer AG
- 15.6.4. Genentech Inc.
- 15.6.5. Bristol-Myers Squibb
- 15.6.6. Eisai Co., Ltd.
- 15.6.7. Exelixis Inc
- 15.6.8. Prometheus Laboratories Inc
- 15.6.9. GlaxoSmithKline Plc
- 15.6.10. F. Hoffmann-LA Roche AG